Tag: Leishmaniasis treatment

Leishmaniasis is a neglected tropical disease often impacting impoverished communities, and a significant barrier to treatment is drug accessibility and cost. The cost of Glucantime, a key medication, varies drastically depending on region, distribution channel, and procurement method, highlighting vast inequities in access to life-saving treatment.

Miltefosine, the only oral treatment for leishmaniasis, was originally developed as an anticancer agent before being repurposed for parasitic diseases. Knowing how to obtain miltefosine requires navigating a specific set of procedures, including securing a medical prescription, understanding commercial availability, and adhering to strict safety protocols.

Leishmaniasis is a parasitic disease estimated to affect hundreds of thousands of people annually worldwide, with a historical reliance on injectable treatments. The development of miltefosine, the first and only recognized oral drug for leishmaniasis, marked a significant advancement in therapeutic options for this neglected tropical disease.